315 related articles for article (PubMed ID: 17870550)
1. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Valat JP; Deray G; Héloire F
Presse Med; 2006 Sep; 35 Suppl 1():25-34. PubMed ID: 17870550
[TBL] [Abstract][Full Text] [Related]
2. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Valat JP; Deray G; Héloire F
Presse Med; 2006 Sep; 35(9 Spec No 1):1S25-34. PubMed ID: 17078592
[TBL] [Abstract][Full Text] [Related]
3. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis.
Gunter BR; Butler KA; Wallace RL; Smith SM; Harirforoosh S
J Clin Pharm Ther; 2017 Feb; 42(1):27-38. PubMed ID: 28019014
[TBL] [Abstract][Full Text] [Related]
4. [What do we know about the cardiovascular toxicity of the NSAIDs?].
Sibilia J; Deray G; Montalescot G
Presse Med; 2006 Sep; 35(9 Spec No 1):1S11-23. PubMed ID: 17078591
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular issues of COX-2 inhibitors and NSAIDs.
Wong M; Chowienczyk P; Kirkham B
Aust Fam Physician; 2005 Nov; 34(11):945-8. PubMed ID: 16299629
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
De Vecchis R; Baldi C; Di Biase G; Ariano C; Cioppa C; Giasi A; Valente L; Cantatrione S
Minerva Cardioangiol; 2014 Dec; 62(6):437-48. PubMed ID: 25029569
[TBL] [Abstract][Full Text] [Related]
8. Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
Chen LC; Ashcroft DM
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):762-72. PubMed ID: 17457957
[TBL] [Abstract][Full Text] [Related]
9. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.
Motsko SP; Rascati KL; Busti AJ; Wilson JP; Barner JC; Lawson KA; Worchel J
Drug Saf; 2006; 29(7):621-32. PubMed ID: 16808554
[TBL] [Abstract][Full Text] [Related]
10. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with celecoxib and rofecoxib utilization.
Rawson NS; Nourjah P; Grosser SC; Graham DJ
Ann Pharmacother; 2005 Apr; 39(4):597-602. PubMed ID: 15755796
[TBL] [Abstract][Full Text] [Related]
12. [Withdrawal of rofecoxib: a sign to be careful with coxibs in patients with increased cardiovascular risk].
Bijlsma JW
Ned Tijdschr Geneeskd; 2004 Oct; 148(44):2162-4. PubMed ID: 15559407
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
[TBL] [Abstract][Full Text] [Related]
14. COX-2 inhibitors and arterial hypertension: an analysis of spontaneous case reports in the Pharmacovigilance database.
Durrieu G; Olivier P; Montastruc JL;
Eur J Clin Pharmacol; 2005 Sep; 61(8):611-4. PubMed ID: 16133552
[TBL] [Abstract][Full Text] [Related]
15. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk.
Moore RA; Derry S; McQuay HJ
BMC Musculoskelet Disord; 2007 Aug; 8():73. PubMed ID: 17683540
[TBL] [Abstract][Full Text] [Related]
16. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.
Mamdani M; Juurlink DN; Lee DS; Rochon PA; Kopp A; Naglie G; Austin PC; Laupacis A; Stukel TA
Lancet; 2004 May; 363(9423):1751-6. PubMed ID: 15172772
[TBL] [Abstract][Full Text] [Related]
17. COX-2 inhibitors and the heart: are all coxibs the same?
Sooriakumaran P
Postgrad Med J; 2006 Apr; 82(966):242-5. PubMed ID: 16597810
[TBL] [Abstract][Full Text] [Related]
18. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care.
Wolfe F; Zhao S; Pettitt D
J Rheumatol; 2004 Jun; 31(6):1143-51. PubMed ID: 15170928
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
McGettigan P; Henry D
JAMA; 2006 Oct; 296(13):1633-44. PubMed ID: 16968831
[TBL] [Abstract][Full Text] [Related]
20. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.
Hudson M; Richard H; Pilote L
BMJ; 2005 Jun; 330(7504):1370. PubMed ID: 15947399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
